In the absence of an RCT directly comparing first-line treatment options for NSCLC of PD-L1–negative expression, our findings suggest that two combined therapies, nivolumab plus ipilimumab plus chemotherapy, and nivolumab plus chemotherapy plus bevacizumab, both appear the most effective therapeutic strategies for this patient population in terms of OS and PFS, respectively. The gene discussed is CD274; the disease is non-small cell lung carcinoma.